Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non–small cell lung cancer (NSCLC).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Corey J. Langer, Antoinette J. Wozniak, Mark A. Socinski, Larry Leon, Shiyao Liu, Sebastien Hazard, Suresh S. Ramalingam
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2936989178